Anavex Life Sciences NASDAQ: AVXL is a short-term candidate as its share prices rise on good news, institutional and analyst support increases, and shorts sell on the upswing. Short interest topped 23% in late November and is unlikely to have fallen much since then as it has surged to a one-year high, showing strong belief there is plenty of fuel for a short squeeze.
Anavex Life Sciences Today
Anavex Life Sciences
(As of 5:45 p.m. ET)
- 52 week range
- US$3.25
▼
$14.44
- Target price
- $44.00
However, the rise that began in late October was driven by positive results from the 2b/3 trial, which showed a more than 36% reduction in Alzheimer’s disease progression in the target group. The company’s potential sales are estimated at more than $15 billion. This is good news for the pharmaceutical company and investors, and it is compounded by numerous details that suggest a short squeeze is coming. Once daily dosing makes it easy to use and safer than non-oral competitors. It is unlikely to require the same level of monitoring and is a revolutionary product in the industry.
A treatment called Anavex 2-73 and called blarcamesine was even more effective (almost 50%) in a small subgroup. It may also be effective in treating a wide range of CNS diseases. If so, the potential market value exceeds the $20 billion mark in annual sales. Sales may begin soon. The company has already applied for marketing approval in the EU. He could receive it as early as the first half of 2025, which would allow him to begin generating significant income by the end of the year.
Analysts and institutions forecast tailwind for Anavex share price
Analysts are bullish on the stock, but have yet to adjust their revenue and earnings forecasts to reflect the EU approval of blarcamesine and its potential to disrupt the market. Analyst coverage is also thin: MarketBeat only tracks four, meaning a strong cycle of updates, including coverage expansion, is coming. In fact, the projections are robust: the company is expected to generate more than $8 billion in annual sales and $40 per share in earnings by 2032. blarcamesine potential, so the earnings estimate update cycle could start in early 2025 and be vigorous.
Anavex Life Sciences stock forecast for today
$44.00
Growth potential 250.32%Buy
Based on ratings of 3 analysts
| High forecast | $46.00 |
|---|---|
| Average forecast | $44.00 |
| Low forecast | $42.00 |
Anavex Life Sciences Stock Forecast Details
Analyst sentiment and stock price targets are bullish and warming. The consensus of four is a buy with a price target of $43, which is about 400% above the critical target resistance level. The most recent targets are in line with this forecast, set following the release of the blarcamesine news, and are likely to be followed by increased coverage and price targets in 2025. The critical detail is that the consensus is well above the $10.50 resistance target and is likely to be reached. quickly if the target is broken.
Institutional activity is providing additional boost to this biopharmaceutical market and is likely to continue or accelerate its trend in 2025. The institutions, which own only about 32% of the stock, made on-balance sheet purchases every quarter in 2024, with overall activity increasing in the fourth quarter. . Buying activity outpaced selling by nearly 1.5 to 1 in the fourth quarter, reaching a nearly two-year high, as institutions like Charles Schwab and Vanguard Group were able to take advantage of the opportunity.
Anavex Life Sciences’ strong technical performance points to strong growth potential
The technical outlook for Anavex shares is bullish. The market is showing strong rising support from significant moving averages, echoed by the MACD and stochastic indicators. The bottom line is that upward price pressure is building and the market still has some way to go before it becomes overbought. It is likely to move above the critical resistance point.
A simple target for bullish traders is a move above the critical $10.50 level, equal to the value of the prior reversal pattern price of $7.15. Thus, the market price is approaching $17.65, which is significantly below the analyst consensus. The bullish scenario is a move above critical resistance equal to the percentage gain from the bottom of the head and shoulders reversal pattern to the neckline, which is 230%. A 230% move would take this market to $35, still well below analyst consensus but well on its way.
Before you consider Anavex Life Sciences, you need to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing analysts daily and the stocks they recommend to their clients. MarketBeat identified five stocks that top analysts were quietly telling their clients to buy now, before the broader market caught on… and Anavex Life Sciences wasn’t on the list.
While Anavex Life Sciences currently has an analyst rating of Buy, the top-rated analysts rate these five stocks as Outperform Buys.
View five stocks here
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to find out when Elon Musk will finally allow these companies to IPO.
Get this free report